Clinical trials recruiting for Small Cell Lung Cancer Extensive Stage

Phase breakdown

Drugs and treatments being studied

Where trials are recruiting (top US states)

Top cities

Self-screener

Recruiting trials

• A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
  NCT07227597 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 52 locations
• A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
  NCT06954246 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
  NCT07625644 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 62 locations
• DSP-0390 in Combination With Atezolizumab for Small Cell Lung Cancer
  NCT07545954 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC
  NCT05745350 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• IN10018 Combination Therapy in Treatment-naïve ES-SCLC
  NCT06030258 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 3 locations
• Liposomal Irinotecan and Apatinib in ES-SCLC
  NCT06749691 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Molecular Analysis and Treatment Options of SCLC
  NCT05945745 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC)
  NCT06610734 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer
  NCT06429696 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)
  NCT07139990 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC
  NCT06348797 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients
  NCT05703971 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 17 locations
• The EASE Study: Randomized Trial of a Novel Approach to Addressing Fear of Progression in Advanced Cancer
  NCT07636200 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 2 locations

Related conditions

Trials recruiting for Small Cell Lung Cancer Extensive Stage often also study these conditions. Each links to its own recruiting-trial list.

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for Small Cell Lung Cancer Extensive Stage trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.